Thrivent Financial for Lutherans
Position in PTCT — Ptc Therapeutics, Inc.
CIK 314984
Minneapolis, MN
Position in PTCT
as of Mar 31, 2026
· filed May 1, 2026
Position Value
$3,651,086
-$539,551 QoQ
Shares Held
53,590
-2.9% QoQ
Ownership
0.065%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
6 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in PTCT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Thrivent Financial for Lutherans holds $270,833,554 across 48 Biotechnology names. PTCT ranks #15 (1.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
|
1,568,627 | $67,278,411 | |
| 2 | BMRN |
Biomarin Pharmaceutical Inc
|
627,699 | $35,458,716 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
75,977 | $33,926,767 | |
| 4 | RPRX |
Royalty Pharma plc
|
499,167 | $23,945,040 | |
| 5 | TECH |
BIO-TECHNE Corp
|
302,934 | $15,831,330 | |
| 6 | ARGX |
Argenx SE
|
12,682 | $9,261,030 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
20,470 | $6,772,908 | |
| 8 | REGN |
Regeneron Pharmaceuticals, Inc.
|
8,440 | $6,521,080 |
All Filings in PTCT
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,651,086 | 53,590 | Shares | Sole | 2026-05-01 | |
| 2025-12-31 | $4,190,637 | 55,169 | Shares | Sole | 2026-02-05 | |
| 2024-12-31 | $918,102 | 20,339 | Shares | Sole | 2025-02-10 | |
| 2024-09-30 | $1,450,535 | 39,098 | Shares | Defined | 2024-11-07 | |
| 2024-03-31 | $984,754 | 33,852 | Shares | Defined | 2024-05-14 | |
| 2023-12-31 | $932,960 | 33,852 | Shares | Sole | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||